Most primary cutaneous B-cell lymphomas (CBCLs) constitute a distinct clinicopathological entity that has a favorable prognosis and displays little tendency to systemic spread. Prognosis is generally independent of histopathological type.
Whether any correlation exists between clinical features and prognosis is open for discussion. Some clinicians think there is none, whereas others believe that multicentricity is a significant prognostic variable. In a recent issue of the Archives, Vermeer et al1 proposed that large B-cell lymphoma of the legs has an intermediate prognosis. It is hoped that additional studies will clarify which of these views is correct.
The main area of international debate, however, is the biological origin of primary CBCL and the reason for its favorable prognosis. Giannotti and Santucci2 proposed that primary CBCL could be considered the cutaneous counterpart of mucosa-associated lymphoid tissue lymphoma. I fully support this view, but I recommend the term marginal zone lymphoma. Implicit
Slater D. Primary Cutaneous B-Cell Lymphomas. Arch Dermatol. 1997;133(12):1604–1605. doi:10.1001/archderm.1997.03890480130024